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Jaana Kantolal, Gloria Blanco*, Anne Hautala3, Tero Kunnari3, Juha Hakala3, 
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Background: Mithramycin, nogalamycin and aclacinomycins are aromatic 
polyketide antibiotics that exhibit antitumour activity. The precursors of these 
antibiotics are formed via a polyketide biosynthetic pathway in which acetate 
(for mithramycinone and nogalamycinone) or propionate (for aklavinone) is used 
as a starter unit and nine acetates are used as extender units. The assembly of 
building blocks is catalyzed by the minimal polyketide synthase (PKS). Further 
steps include regiospecific reductions (if any) and cyclization. In the 
biosynthesis of mithramycin, however, ketoreduction is omitted and the regio- 
specificity of the first cyclization differs from that of anthracycline antibiotics 
(e.g. nogalamycin and aclacinomycins). These significant differences provide a 
convenient means to analyze the determinants for the regiospecificity of the first 
cyclization step. 
Results: In order to analyze a possible role of the minimal PKS in the 
regiospecificity of the first cyclization in polyketide biosynthesis, we expressed 
the mfm locus, which includes mithramycin minimal PKS genes, in 
Streptomyces galilaeus, which normally makes aclacinomycins, and the sno 
locus, which includes nogalamycin minimal PKS genes, in Streptomyces 
argillaceus, which normally makes mithramycin. The host strains are defective in 
the minimal PKS, but they express other antibiotic biosynthesis genes. 
Expression of the sno minimal PKS in the S. argillaceus polyketide-deficient 
strain generated mithramycin production. Auramycins, instead of 
aclacinomycins, accumulated in the recombinant S. galilaeus strains, 
suggesting that the mithramycin minimal PKS is responsible for the choice of 
starter unit. We also describe structural analysis of the compounds 
accumulated by a ketoreductase-deficient S. galilaeus mutant; spectroscopic 
studies on the major polyketide compound that accumulated revealed a first 
ring closure which is not typical of anthracyclines, suggesting an important role 
for the ketoreductase in the regiospecificity of the first cyclization. 
Conclusions: These experiments clearly support the involvement of 
ketoreductase and a cyclase in the regiospecific cyclization of the biosynthetic 
pathway for aromatic polyketides. 
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Introduction 
Aromatic polyketides are a large group of structurally diverse 
natural products that exhibit a broad range of biological acti- 
vities. Nevertheless, they share a common biosynthetic 
pathway in which single carboxylic acid residues (often 
acetates) are used to build up a polyketide chain in a reac- 
tion catalyzed by polyketide synthase (PKS). The enzyme 
complex responsible for forming the polyketide chain is the 
minimal PKS, which probably controls the choice of the 
starter unit and the number of extenders used in the assem- 
bled polyketide chain, thereby allowing variability in the 
polyketide backbones. In addition, the degree of reduction 
and regiospecific cyclizations of the polyketide chain gives 
structural diversity to the aromatic polyketides formed. 
Mithramycin [l], aclacinomycins [Z] and nogalamycin [3] 
(Figure 1) are aromatic polyketide antibiotics that exhibit 
powerful antitumour properties. Nogalamycin and acla- 
cinomycin belong to the anthracycline group and mithra- 
mycin belongs to the aureolic acid group of antibiotics. 
The structures of the aglycone moieties in these two anti- 
biotic groups differ remarkably from each other (Figure 1). 
Anthracyclinone, the aglycone moiety of anthracyclines, is 
formed from the starter unit propionate or acetate and 
nine acetate extender units. Aklavinone, the aglycone 
moiety of aclacinomycins and a precursor of many other 
anthracyclines, uses propionate as a starter unit, whereas 
in nogalamycin biosynthesis, acetate is chosen to be the 
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Figure 1 
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The structures of (a) aclacinomycin A and 
auramycin A, (b) nogalamycin, (c) mithra- 
mycin, and (d) compound I derived from 
HO61. Nogalamycin and aclacinomycin 
belong to the anthracycline group of 
antibiotics and mithramycin belongs to the 
aureolic acid group. 
starter unit. In both cases following the addition of nine 
acetate units to the primer, ketoreduction occurs at position 
nine (calculated from the carboxyl terminus; corresponding 
to C-2 in anthracyclines; Figure 1) and the intramolecular 
cyclization occurs at positions seven and 12 in the nascent 
polyketide chain (between C-7 and C-12 in anthracyclines). 
Similarly, mithramycinone is synthesized from ten acetates, 
but, in contrast to anthracyclinone biosynthesis, the keto- 
reduction does not occur at the polyketide stage and the 
first ring closure is formed between C-9 and C-14 in a 
similar manner to early tetracenomycin intermediates [4-71. 
Studies of the biosynthesis of aromatic polyketides have 
been successful due to the structural analysis of several 
compounds synthesized by combinations of polyketide 
genes from different producers [S]. But because the com- 
pounds formed are derived from highly reactive early inter- 
mediates for biosynthesis, elucidation of the functions of 
the first enzymes participating in polyketide biosynthesis 
is complicated. Indeed, it is not clear which enzymes are 
really needed to determine the folding of a polyketide 
chain, and several possibilities have been suggested. A 
role for the minimal PKS in the first cyclization using 
individual genes was discussed by Fu et al. [9] in studies 
suggesting temporal control of cyclization. But studies of 
tetracenomycin biosynthesis, where a polyketide chain is 
not a substrate for a ketoreductase, suggest that a polyke- 
tide cyclase, rather than the minimal PKS, determines the 
first cyclization [lo]. Furthermore, Kramer et al. [ll] sug- 
gested that the auxiliary subunits of PKS determine the 
size and folding pattern of the polyketide chain. 
Here, we report the expression of mtm mithramycin mini- 
mal PKS genes in Streptomyces galilaew HO28 and HO39 
mutants and of the sno nogalamycin minimal PKS genes in 
the Streptomyces argillaceus polyketide-deficient (PK-) strain. 
The target strains HO28 and PK- were blocked in an early 
step of biosynthesis for aclacinomycins and mithramycin, 
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Figure 2 
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Expression constructs for nogalamycin PKS (pSY21) and mithramycin 
PKS (pGB7). A, snoA; 1, snol; 2, NO.!?; 3, sno3; X, mtmX; P, mtmP; 
K, mtmK; S, mtmS; Tl, mtmT7; 01, mtmO7 (not complete). See 
Materials and methods section for gene functions. 
respectively; both strains failed to accumulate any coloured 
compounds in liquid cultures. Thus, this study supports 
the conclusion that the minimal PKS does not dictate the 
regiospecificity of the first cycliLation. 
Results and discussion 
\\:e recently cloned the genes for nogalamycin PKS and 
reported their expression in S’. &i/&w [12]. The minimal 
PKS was cloned in plasmid pIJ486 to give pSY21 which, in 
addition to the minimal PKS open reading frames (ORFs; 
.sno1-sw.?), contains .woA, an acti\-ator promoting the 
expression of the minimal PKS genes (Figure 2). Aura- 
mycins were produced by pSY21 in S. g/ik~e~s strains [12]. 
11.hen pSYZ1 \vas introduced into the S’. q@/kueu PK- 
mutant, transformants produced only mithramycin. ‘l’his 
\vas \,erified by purifying mithramycin from the wild-type 
strain and analyzing by ‘H and ‘.iC nuclear magnetic reso- 
nance (MlR) spectroscopy: the resonances detected for 
the compound isolated from the recombinant strain PK-/ 
pSY21 corresponded to the spectroscopic data of mithra- 
mycin found in the literature. The products accumulated 
by the recombinant strain were compared with those of 
the wild-type strain and it \vas found that a higher yield of 
mithramycin was obtained by the PK- mutant carrying 
pSY21 even though all the compounds were accumulated 
by the wild type as well. In Figure 3, the high perfor- 
mance liquid chromatography (HPLC) traces for the 
samples are shown. The recombinant strain PK-/pSYZl 
accumulated mithramycin, but not the compounds sharing 
the folding pathway of anthracyclines (Figure 4), suggest- 
ing that the regiospecificity of the first ring formation in 
this case is not dictated by minimal PKS. 
A gene cluster encoding the mithramycin PKS (Figure 2) 
was previously isolated and characterized [5,13]. The genes 
for the minimal PKS (Figure 2) were cloned into Strepto- 
m,vus lizidcl?u TK24 and transferred into the S. gzllikueus 
Figure 3 
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High performance liquid chromatography (HPLC) traces of the 
samples from (a) wild-type Sfreptomyces argikeus, (b) PK-, and 
(c) PK-/pSYPl The major peak (retention time = 13 min) corresponds 
to mithramycin. Minor products were not identified. 
mutants, H039 and H02X. HO39 is a mutant blocked in 
rhodosamine and deoxyfucose biosynthesis, but a-as used 
here because of a higher transformation frequency than 
in the other mutants or the wild-type A’. ,qolikueu.s. The non- 
producing mutant chosen, H028, was previously shown 
to be complemented by the genes for the nogalamycin 
PKS. resulting in the production of auramyins. SimilarI?-, 
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Figure 4 
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expression of the MTM genes in HO28 and HO39 resulted in 
the production of auramycins. Nevertheless, the compound 
with the largest fraction of the total products was found to 
be auramycinone, by comparing to a standard by thin layer 
chromatography (TLC) and HPLC and by confirming the 
structure of a purified major product from HO39/pGB7 by 
mass spectroscopy. The main signals detected were at m/z 
(5%): 39X hl+ (12) 380 (15), 362 (lo()), 347 (16) 331 (30), 321 
(35) and 303 (13). The accumulation of auramycins in the 
S. &i&us mutants expressing the mithramycin minimal 
PKS suggests that the host strain determines the folding of 
a polyketide chain, whereas the use of acetate as the starter 
unit in biosynthesis is dictated by rntfn genes. 
HO61 is a polyketide ketoreductase deficient mutant 
derived from the aclacinomycin biosynthetic pathway (as 
shown by complementation by a gene encoding a nogala- 
mycin polyketide ketoreductase, KR [12]). The struc- 
tural analysis of the main product compound I, 60% of 
the whole extract obtained from the culture, revealed a 
structure in which the first intramolecular condensation 
had occurred between C-10 and C-15 (see Figure la); 
this is different from the condensation seen between C-7 
and C-12 in anthracyclines (e.g. auramycinone, Figure 4). 
Thus, the structure of the main product seen here sug- 
gests that the folding of a linear polyketide chain in 
PKSs that contain KR is influenced by the KR subunit. 
Significance 
Nogalamycin, mithramycin and aclacinomycins are 
aromatic polyketide antibiotics that exhibit antitumour 
activity. Using genes encoding the minimal polyketide 
synthase (PKS) for nogalamycin and mithramycin bio- 
synthesis (which have different patterns of ketoreduc- 
tion and first cyclization) in Streptomyces strains that 
lack endogenous minimal PKS activity, we have demon- 
strated that the folding of a polyketide chain is not dic- 
tated by the minimal PKS. This study also demonstrates 
the usefulness of the blocked mutants in analyzing the 
functions of the genes, because the unwanted shunt 
products (formed by spontaneous reactions and not used 
as intermediates for biosynthesis) derived from highly 
reactive intermediates that appear in genetic engineering 
systems are avoided. The concomitant action of the PKS 
genes influences the structure formed, making it difficult 
to analyze the functions of individual genes in the system 
missing the structural PKS components. It is possible 
that the enzyme complex binds the nascent polyketide 
Research Paper Folding of an aromatic polyketide chain Kantola et al. 755 
chain, keeping it in the correct orientation to promote 
the catalytic activities of the proteins. Mutants that have 
intact enzymes, but missing catalytic activities, might be 
suitable tools for determining the functions of the genes. 
In this study, PKS components other than the mini- 
mal PKS were expressed in the host strains, thereby 
demonstrating that the minimal PKS is not essential for 
regiospecilic cyclization. 
Materials and methods 
Bacterial strains, plasmids, and culture conditions 
S. arglllaceus ATCC 12596 is a mithramycin producer and S. galilaeus 
ATCC 31615 IS an aclacinomycin producer strain. A non-producing 
S. galilaeus mutant HO28 was obtained by NTG (N-methyl-N’-nitro- 
N-nitrosoguanide) mutagenization of the wild type [141. HO61 is an 
S. galilaeus mutant deficient in polyketide ketoreductase [14]. S. gali- 
laeus HO39 is blocked in rhodosamine and deoxyfucose biosynthesis 
[14], but the relevant characteristic here is a better transformation of 
HO39 than that of the wild type or other mutants. The S. argillaceus PK- 
mutant has a deletion affecting the mtmP and mtmK genes of the 
mithramycin mrnimal PKS [13]. Plasmid pSY21 contains the genes for 
the mmimal PKS of nogalamycin biosynthesis and the regulator gene 
snoA encoding an actrvator that promotes the expression of the minimal 
PKS genes [12]. Plasmid pGB7 is a pWHM3 derivative that contains the 
genes for the mithramycin minimal PKS (mfmP, mtrnK and mtmS) in addi- 
tion to three other genes (mtmX encodes presumably the last cyclase in 
mithramycinone biosynthesis; mtmT1 encodes a putative ketoreductase 
and an incomplete mtmO1; [7,13]). pSY21 was introduced into the 
S. argillaceus wild type and into the PK- mutant by protoplast transfor- 
mation. In the same manner, pGB7 was propagated in S. lividans and 
subsequently introduced into HO39 by transformation. Plasmids isolated 
from HO39 were then introduced into the S. galilaeus blocked mutant, 
H028. Transformants were selected for thiostrepton resistance. 
Production and identification of compounds 
El medium containing glucose (20 g/l), starch (20 g/l), Pharmamedia 
(Trader’s protein; 5 g/l), yeast extract (2.5 g/l), CaCO, (3 g/l), NaCl 
(1 g/l), MgSO,.7H,O (1 g/l) and K,HPO, (1 g/l) in tap water (pH 7.5) 
was used to produce anthracyclines and mithramycin. Cultivation was 
carried out in 250 ml Erlenmayer flasks containing 60 ml of El medium at 
30°C for 4-7 days in a rotary shaker at 300 rpm. Culture samples, 
adjusted to pH 7, were extracted with methanol-chloroform (1 :2). Chloro- 
form extracts were dried and the production profiles were determined by 
HPLC on a Merck-Hitachi instrument (L-6200A/L-4250) using a Merck 
LiChrocart RP-18 column. The eluent used was a gradient of acetonitrile: 
potassium dihydrogen phosphate buffer (60 mM; pH 3.0 adjusted with 
citric acid). The flow-rate was 1 ml/min and detection was at 420 nm. 
The purification of the main product from H039/pGB7 was done by 
preparative thin-layer chromatography using Silica Gel 6OF,,, (Merck & 
Co.). Development was done with toluene:ethyl acetate:methanol:formic 
acid (50:50:15:10, by vol.). Mass spectroscopy was performed on a 
Varian VG707E spectrometer. 
Isolation of the HO61 product 
Strain HO61 was grown in a 10 I fermenter (El -medium, 28°C 500 rpm, 
20 I/min) for 6 days. Compounds were extracted separately from mycelia 
and supernatant with dichloromethanelmethanol at pH 3.0. Solvents 
were removed under vacuum and viscous residue was flashed through 
a polyamide 1 1 column, eluent being water:methanol (1 :9 to 0:lO). 
Fractrons were further purified on a Merck-Hitachi HPLC using prepara- 
tive reversed phase column C-l 8 (mobile phase; acetonitrile:phosphate 
buffer 1 :l). 
Nuclear magnetic resonance spectroscopy 
‘H and 13C NMR spectra were recorded on a JEOL JNM-GX400 spec- 
trometer using DMSO-d, as a solvent, NMR-analysis also included 
nuclear Overhauser enhancement (NOE) difference, DEPT and HMBC 
techniques. Spectra were internally referenced to tetramethylsilane. 
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